The scientific hurdle for malaria vaccines is largely cleared. A Phase 4 interim analysis in The Lancet Global Health this May tracked RTS,S/AS01E in Ghana, Kenya, and Malawi through routine medical practice and found effectiveness matching clinical-trial results: reduced malaria incidence, severe malaria, hospitalizations, and anemia over one year of follow-up.
Over four years of pilot implementation, WHO estimates roughly 1 in 8 child deaths were averted among eligible children in the three pilot countries. That is empirical evidence at population scale, not a controlled-study artifact.
R21/Matrix-M, developed at Oxford and manufactured by Serum Institute of India with Novavax adjuvant, is now also WHO-prequalified, with trial efficacy of 68–75%. Having two prequalified vaccines should ease supply pressure, though both require multi-dose schedules and high community adherence.
Yet global supply exceeds current country demand, and many African countries still cannot scale to national targets or sustain coverage already achieved. The Serum Institute projects immunizing 50 million additional children by 2030 and averting ~170,000 deaths — but only if financing materializes. The bottleneck has shifted from the vial to the procurement budget, the cold chain, and the community health system.
Sources:
– The Lancet Global Health — RTS,S/AS01E Phase 4 interim effectiveness00089-3/fulltext)
– WHO — Malaria vaccine implementation programme
– Gavi — Malaria vaccine funding and rollout